Nufymco Injection, Solution
NDC Package 70710-2173-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Nufymco (ranibizumab-leyk) injection is a medication used to treat certain serious eye conditions (such as age-related macular degeneration, macular edema, diabetic retinopathy). This formulation utilizes a injection, solution delivery system. Marketed by Zydus Pharmaceuticals Usa Inc., this product is identified by NDC 70710-2173 and is authorized under FDA application BLA761473.

Identification & Billing

NDC Package Code
70710-2173-1
Package Description
1 VIAL, GLASS in 1 CARTON / .05 mL in 1 VIAL, GLASS
Product Code
70710-2173
11-Digit Billing Format
70710217301

Clinical Specifications

Proprietary Name
Nufymco
Non-Proprietary Name
Ranibizumab-leyk
Substance Name
Ranibizumab
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravitreal - Administration within the vitreous body of the eye.
Active Ingredient(s)
RANIBIZUMAB .5 mg/.05mL
Pharmacologic Class
Usage Information
This medication is used to treat certain serious eye conditions (such as age-related macular degeneration, macular edema, diabetic retinopathy). It is used to help prevent decreased vision and blindness. Ranibizumab works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels.

Regulatory & Marketing

Labeler Name
Zydus Pharmaceuticals Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761473
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
06-11-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70710-2173-1 identifies a specific commercial package of 1 vial, glass in 1 carton / .05 ml in 1 vial, glass of Nufymco, a human prescription drug labeled by Zydus Pharmaceuticals Usa Inc.. This injection, solution is formulated for intravitreal use and contains ranibizumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Pharmaceuticals Usa Inc. on June 11, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat certain serious eye conditions (such as age-related macular degeneration, macular edema, diabetic retinopathy). It is used to help prevent decreased vision and blindness. Ranibizumab works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels.

How is this Zydus Pharmaceuticals Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70710217301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70710-2173-1
11-Digit CMS (5-4-2)
70710-2173-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.